Nat is an Infectious Diseases physician with more than 35 years of academic and pharmaceutical industry experience. Nat has extensive industry experience with all phases of pharmaceutic development, having held leadership roles in U.S. and global clinical programs for 12 novel anti-infective agents for hepatitis C, hepatitis B and HIV/AIDS, including global clinical development leadership for two currently marketed HBV nucleoside analogs and U.S. FDA registration programs for atovaquone (for Pneumocystis pneumonia in HIV patients), AZT for children with AIDS, acyclovir for Varicelle-Zoster infection, and lymphoblastoid interferon for hepatitis C.
In addition to serving as Atea’s Chief Medical Advisor, Nat currently serves as a Director of the Hepatitis B Foundation and as Adjunct Professor of Experimental Therapeutics with the Hepatitis B Foundation’s Blumberg Research Institute.
Previously, Nat served as Chief Medical Officer (CMO) at Novira Therapeutics (acquired by Johnson & Johnson in 2015), and as CMO for Presidio Pharmaceuticals and Idenix Pharmaceuticals. Prior to joining Idenix, Nat was Section Head at GlaxoWellcome/GlaxoSmithKline for 11 years (Hepatitis Section for 7 years, Opportunistic Infections Section for previous 4 years). Nat has consulted for the FDA’s Division of Antiviral Drug Products and has served as a reviewer for the NIH Division of Extramural Grants.
Before joining industry, Nat was engaged for 8 years on a full-time basis in academic medicine at UCLA and then Cornell, progressing to Associate Professor and Division Head, with continuous NIH R01 research funding for viral research and service on NIH committees. Nat has authored or co-authored over 200 published research articles, chapters, and scientific abstracts.
Nat did his undergraduate studies in Molecular Biophysics & Biochemistry at Yale and holds an MD from Georgetown University School of Medicine. He completed his clinical and research training at Weill-Cornell Medical Center and Yale U. School of Medicine.Back to Full Team